01—Abstract
Summary
Summary of the 8-K filed October 6, 2026. Cited figures are marked; the original filing is the authoritative source.
Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K detailing a significant amendment to its existing License and Collaboration Agreement (LCA) with Sanofi.
This Sixth Amendment focuses on the co-development and co-commercialization of four novel, Regeneron-invented long-acting antibodies targeting key inflammatory pathways (IL-13, IL-4, IL-4Rα, and a bispecific IL-4xIL-13). This strategic move significantly expands Regeneron's pipeline in high-potential therapeutic areas. The financial implications for Regeneron are substantial.
Sanofi will provide an upfront payment of $1.0 billiona, with the potential for an additional $7.0 billion in milestone payments tied to development, regulatory, and commercial success. This partnership also includes a balanced approach to cost-sharing for development, with Regeneron acting as the lead development and regulatory party in the U.S. Additionally, the report discloses an expected $22 million pre-tax acquired in-process R&D charge for Q3 2026, impacting EPS by approximately $0.18. The settlement of a prior lawsuit regarding Dupixent commercialization information is also a notable event.
02—Key points
Key Highlights
- Regeneron enters into the Sixth Amendment to its Antibody LCA with Sanofi, agreeing to co-develop and co-commercialize four new Regeneron-invented long-acting antibodies targeting IL-13, IL-4, and IL-4Rα.
- Sanofi will pay Regeneron an upfront fee of $1.0 billion, with up to an additional $7.0 billion in potential milestone payments contingent on development, regulatory, and commercial achievements.
- Regeneron has an option to include Sanofi's Phase 2/3 asset lunsekimig and another early development product in the collaboration, subject to reimbursement of certain development costs.
- Global profits from the New Licensed Products will be shared equally between Regeneron and Sanofi.
- Regeneron will serve as the lead development and regulatory party for the New Licensed Products in the U.S., while Sanofi will lead commercialization globally and regulatory outside the U.S.
- Regeneron expects a pre-tax acquired in-process R&D charge of approximately $22 million for Q3 2026, estimated to reduce EPS by $0.18.
- Regeneron and Sanofi have entered into a settlement agreement, leading to the dismissal of Regeneron's lawsuit concerning access to commercialization information and audit rights for Dupixent and other products.
03—Questions
Frequently Asked Questions
What is the primary focus of the Sixth Amendment to the Antibody LCA?
The Sixth Amendment focuses on the co-development and co-commercialization of four new, Regeneron-invented long-acting antibodies targeting inflammatory pathways (IL-13, IL-4, IL-4Rα, and a bispecific IL-4xIL-13). It significantly expands the collaborative efforts between Regeneron and Sanofi in these therapeutic areas.
What are the potential financial benefits for Regeneron from this agreement?
Regeneron is set to receive a $1.0 billion upfront payment from Sanofi, with the potential to earn up to an additional $7.0 billion through milestone payments based on the success of the New Licensed Products. Furthermore, Regeneron will share equally in the global profits generated from these products.
How will development costs be handled under the new agreement?
Development costs for all licensed products under the Antibody LCA, including the New Licensed Products, will be shared equally by Regeneron and Sanofi. Regeneron will be the lead development party for each New Licensed Product. However, Regeneron will be responsible for development costs exceeding a budget cap, with certain rights to recoup these excess costs in the future.
What impact is the acquired in-process R&D charge expected to have on Regeneron's financials?
Regeneron anticipates a pre-tax acquired in-process R&D charge of approximately $22 million for the third quarter of 2026. This is expected to negatively impact both GAAP and non-GAAP net income per diluted share by approximately $0.18 for the quarter.
04—Continue